Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, June 30, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2025 (2025-06-30): -856.02%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-360.64%
RETURN ON EQUITY (ROE) AVG 3Y
-53.56%
RETURN ON EQUITY (ROE) AVG 5Y
-39.88%
RETURN ON EQUITY (ROE) AVG 10Y
-69.38%
RETURN ON EQUITY (ROE) AVG 15Y
-75.75%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Pacific Biosciences of California, Inc.
Market Cap
$848.07M
Return on Equity (ROE)
N/A
TTM Avg
-360.64%
3Y Avg
-53.56%
5Y Avg
-39.88%
Market Cap
$848.38M
Return on Equity (ROE)
-59.07%
TTM Avg
-63.84%
3Y Avg
-29.19%
5Y Avg
-3.25%
Market Cap
$839.96M
Return on Equity (ROE)
-28.46%
TTM Avg
-48.75%
3Y Avg
-33.66%
5Y Avg
-33.66%
Market Cap
$842.52M
Return on Equity (ROE)
-24.12%
TTM Avg
40.34%
3Y Avg
40.34%
5Y Avg
40.34%
Market Cap
$860.07M
Return on Equity (ROE)
75.67%
TTM Avg
312.76%
3Y Avg
285.83%
5Y Avg
166.15%
Market Cap
$835.94M
Return on Equity (ROE)
-33.06%
TTM Avg
-24.59%
3Y Avg
-41.17%
5Y Avg
-18.72%
Market Cap
$857.96M
Return on Equity (ROE)
-167.25%
TTM Avg
-94.03%
3Y Avg
-58.96%
5Y Avg
-58.96%
Market Cap
$861.26M
Return on Equity (ROE)
-8.03%
TTM Avg
-14.58%
3Y Avg
-29.27%
5Y Avg
-30.82%
Market Cap
$834.03M
Return on Equity (ROE)
-97.08%
TTM Avg
-96.94%
3Y Avg
-22.72%
5Y Avg
-22.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pacific Biosciences of California, Inc. (PACB) | $848.07M | N/A | -360.64% | -53.56% | -39.88% |
| QuidelOrtho Corporation (QDEL)vs › | $848.38M | -59.07% | -63.84% | -29.19% | -3.25% |
| Beta Bionics, Inc. (BBNX)vs › | $839.96M | -28.46% | -48.75% | -33.66% | -33.66% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $842.52M | -24.12% | 40.34% | 40.34% | 40.34% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $860.07M | 75.67% | 312.76% | 285.83% | 166.15% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $835.94M | -33.06% | -24.59% | -41.17% | -18.72% |
| SL Science Holding Ltd (SLBT)vs › | $857.96M | -167.25% | -94.03% | -58.96% | -58.96% |
| SI-BONE, Inc. (SIBN)vs › | $861.26M | -8.03% | -14.58% | -29.27% | -30.82% |
| Alumis Inc. (ALMS)vs › | $834.03M | -97.08% | -96.94% | -22.72% | -22.72% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | -24.02% | -108.12% | -89.93% | -68.76% |
ROE
N/A
ROA
-17.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | -856.02% |
| 2025-03-31 | -717.77% |
| 2024-12-31 | -61.16% |
| 2024-09-30 | -87.01% |
| 2024-06-30 | -81.26% |
| 2024-03-31 | -45.75% |
| 2023-12-31 | -43.74% |
| 2023-09-30 | -40.47% |
| 2023-06-30 | -49.72% |
| 2023-03-31 | -46.35% |
| 2022-12-31 | -55.83% |
| 2022-09-30 | -47.75% |
| 2022-06-30 | -30.16% |
| 2022-03-31 | -23.86% |
| 2021-12-31 | -22.91% |
| 2021-09-30 | -4.40% |
| 2021-06-30 | -29.90% |
| 2021-03-31 | -21.13% |
| 2020-12-31 | 8.76% |
| 2020-09-30 | -35.23% |
| 2020-06-30 | -123.30% |
| 2020-03-31 | -87.00% |
| 2019-12-31 | -153.20% |
| 2019-09-30 | -225.12% |
| 2019-06-30 | -146.21% |
| 2019-03-31 | -114.61% |
| 2018-12-31 | -89.92% |
| 2018-09-30 | -70.16% |
| 2018-06-30 | -104.71% |
| 2018-03-31 | -90.04% |
| 2017-12-31 | -107.07% |
| 2017-09-30 | -89.20% |
| 2017-06-30 | -74.17% |
| 2017-03-31 | -114.03% |
| 2016-12-31 | -87.84% |
| 2016-09-30 | -57.51% |
| 2016-06-30 | -34.64% |
| 2016-03-31 | -34.78% |
| 2015-12-31 | -43.10% |
| 2015-09-30 | -119.08% |
| 2015-06-30 | -178.05% |
| 2015-03-31 | -166.65% |
| 2014-12-31 | -120.40% |
| 2014-09-30 | -121.46% |
| 2014-06-30 | -128.34% |
| 2014-03-31 | -102.05% |
| 2013-12-31 | -114.62% |
| 2013-09-30 | -100.23% |
| 2013-06-30 | -85.63% |
| 2013-03-31 | -82.16% |
| 2012-12-31 | -86.36% |
| 2012-09-30 | -74.39% |
| 2012-06-30 | -68.94% |
| 2012-03-31 | -60.84% |
| 2011-12-31 | -57.13% |
| 2011-09-30 | -58.37% |
| 2011-06-30 | -57.61% |
| 2011-03-31 | -58.17% |
| 2010-12-31 | -50.08% |
| 2010-06-30 | -87.82% |
